

1. **Luchi ME**, Asherson R, Lahita R: **Primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis; association with anti-phospholipid antibodies.** Arthritis & Rheumatism, June 1992, Vol. 35, No. 6, p700.
2. Beutler A, Keenan G, Solloway S, Norden DK, **Luchi ME**, Schumacher HR Jr.: **Soluble urate in sera and synovial fluids from patients with different joint disorders.** Clinical and Experimental Rheumatology, 1996
3. Ramanujam T, **Luchi ME**, Schumacher HR, et al. **Detection of T cell receptors in early rheumatoid arthritis synovial tissue**
4. **Luchi ME**, Feldman M, Williams WV. **Fatal disseminated herpes simplex II in a patient with systemic lupus erythematosus.** Journal of Rheumatology, Vol. 22, No. 4, p799.
5. **Luchi ME** and Katz WA. **Diagnosis and Management of Arthritis Pain in the Elderly.** Clinical Geriatrics.
6. Reid I, **Luchi ME**, et al. **A Single Infusion of Zoledronic Acid Improves Remission Rates in Paget's Disease: A Randomized Controlled Comparison with Risedronate.** NEJM , Volume 353, No. 9, p898-908.
7. D J Hunter, J Niu, Y Zhang, S Totterman, J Tamez, C Dabrowski, R Davies, M-P Hellio Le Graverand, M **Luchi**, Y Tymofyeyev, C R Beals, Ann Rheum Dis. Author manuscript; available in PMC 2009 Aug 30. [Change in cartilage morphometry: a sample of the progression cohort of the Osteoarthritis Initiative](#) Published in final edited form as: Ann Rheum Dis. 2009 Mar; 68(3): 349–356. Published online 2008 Apr 13
8. Duryea J, **Luchi ME**, et al. **Comparison of radiographic joint space width to MRI cartilage morphometry: analysis of longitudinal data from the Osteoarthritis Initiative (OAI) Arthritis Care and Research,** Volume 62, No. 7. p 932-937.
9. Vaddi K and **Luchi M.** **JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy** (review invited editors of Expert Opinion on Investigational Drugs, July 2012, Vol. 21, No. 7, pp. 961-973.
10. Keystone E, **Luchi Me**, et al. **Protocol I4V-MC-JADA: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients with Active Rheumatoid Arthritis who had had an Inadequate Response to Methotrexate.** Annals Rheum Disease, Feb 2015, 74 (2), pp. 333-340.
11. Edward C Keystone, Peter C Taylor, Edit Drescher, Douglas E Schlichting, Scott D Beattie, Pierre-Yves Berclaz, Chin H Lee, Rosanne K Fidelus-Gort, **Monica E Luchi**, Terence P Rooney, William L Macias, Mark C Genovese, Ann Rheum Dis. **Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate** 2015 Feb; 74(2): 333–340. Published online 2014 Nov 27. doi: 10.1136/annrheumdis-2014-206478 PMID: PMC4316868.

1. Norden DK, Schafritz A, **Luchi ME**, et al. **Catastrophic antiphospholipid antibody syndrome: a series of eight patients.** Presented as a poster at the national ACR meeting 1993, Arthritis & Rheumatism Abstracts #C87, vol 36, no. 9 (sup)
2. Callis Duffin K, **Luchi M**, et al. **Novel mechanism for topical treatment of plaque psoriasis –results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with JAK 1/2 inhibitor INCB018424 cream.** Accepted for poster and oral presentation at the national Society for Investigative Dermatology meeting 2010 and published in society's journal
3. Keystone E, Taylor P, et al **Luchi M**, Macias W. **12-Week Results of a Phase 2b Dose-Ranging Study of LY3009104 (INCB028050) an Oral JAK1/JAK 2 Inhibitor, in Combination with Traditional DMARDs in Patients with Rheumatoid Arthritis**, Late Breaker EULAR meeting 2012
4. Genovese M, Keystone E, et al. 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis accepted for oral presentation ACR meeting 2012
5. Peterfy C, Emory P, **Luchi M.**, et al. **Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis** accepted for oral presentation ACR meeting 2012; follow up submitted to Journal of Rheumatology 2018
6. R. Bissonnette, A. Menter, **Luchi M.**, et al. **A Double-blind, placebo-controlled study exploring the safety, tolerability, and efficacy of a 28-day Course of Escalating doses of oral INCB039110** in subjects with stable, chronic plaque psoriasis, accepted for oral presentation at European Academy of Dermatology and Venerology 2013.
7. **Luchi, M**, et al. **A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis** accepted for oral presentation to ACR meeting 2013
8. Pollak R DPM, **Luchi, M** et al. **Phase 2 Multi-Center Controlled Study to Evaluate Safety and Efficacy of PDA-002 in Diabetic Foot Ulcer with and without Peripheral Arterial Disease**, presented at Innovative Wound Care Conference, Dec 2018 Key West, FLA
9. Nedeljkovic S, **Luchi M** et al. **A Multi-center, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin (RTX) Injection for Treatment of Intractable Pain Associated with Cancer**, presented at American Academy of Pain Medicine, Feb 2020 National Harbor, Maryland

10. Nedeljkovic S, Luchi M, et al. **A Multi-Center, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin (RTX) Injection for Treatment of Intractable Pain Associated with Cancer**, presented at the Annual Pain Therapeutics Summit, Sept 2020
Virtual due to COVID-19